{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0000200406","name":"JOHNSON & JOHNSON","summary":"Johnson & Johnson is a global healthcare holding company with approximately 138,200 employees operating in virtually all countries. It is organized into two segments: Innovative Medicine (pharmaceuticals across oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular/metabolism) and MedTech (cardiovascular, orthopaedics, surgery, and vision products). Key products include DARZALEX, STELARA, TREMFYA, CARVYKTI, SPRAVATO, XARELTO, and ACUVUE contact lenses.","people":[{"name":"Matt","role":"Analyst, Miksic  Barclays Services Corp","role_type":"analyst","period_start":null,"period_end":null,"notes":null}],"products":[{"name":"DARZALEX / DARZALEX FASPRO (daratumumab)","type":"service","description":"Treatment for multiple myeloma and light chain AL Amyloidosis; largest product at ~15% of total revenues."},{"name":"STELARA (ustekinumab)","type":"service","description":"Treatment for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; second largest product at ~6.5% of revenues."},{"name":"TREMFYA (guselkumab)","type":"service","description":"Treatment for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; third largest product at ~5.5% of revenues."},{"name":"CARVYKTI (ciltacabtagene autoleucel)","type":"service","description":"CAR-T-cell therapy for relapsed/refractory multiple myeloma."},{"name":"ERLEADA (apalutamide)","type":"service","description":"Next-generation androgen receptor inhibitor for prostate cancer treatment."},{"name":"IMBRUVICA (ibrutinib)","type":"service","description":"Treatment for B-cell malignancies and chronic graft versus host disease."},{"name":"RYBREVANT (amivantamab)","type":"service","description":"Bispecific antibody for EGFR-mutated non-small cell lung cancer in adults."},{"name":"LAZCLUZE (lazertinib)","type":"service","description":"Oral, brain-penetrant EGFR tyrosine kinase inhibitor for non-small cell lung cancer."},{"name":"TALVEY (talquetamab-tgvs)","type":"service","description":"Bispecific antibody for relapsed or refractory multiple myeloma after four prior lines of therapy."},{"name":"TECVAYLI (teclistamab-cqyv)","type":"service","description":"Bispecific antibody for relapsed or refractory multiple myeloma after four prior lines of therapy."},{"name":"ZYTIGA (abiraterone acetate)","type":"service","description":"Treatment for prostate cancer."},{"name":"REMICADE (infliximab)","type":"service","description":"Treatment for immune-mediated inflammatory diseases."},{"name":"SIMPONI / SIMPONI ARIA (golimumab)","type":"service","description":"Subcutaneous and intravenous treatments for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis."},{"name":"CAPLYTA (lumateperone)","type":"service","description":"Treatment for major depressive disorder, bipolar depression, and schizophrenia in adults."},{"name":"CONCERTA (methylphenidate HCl)","type":"service","description":"Extended-release treatment for attention deficit hyperactivity disorder."},{"name":"INVEGA SUSTENNA / XEPLION (paliperidone palmitate)","type":"service","description":"Treatment for schizophrenia and schizoaffective disorder in adults."},{"name":"INVEGA TRINZA / TREVICTA (paliperidone palmitate)","type":"service","description":"Treatment for schizophrenia in patients previously treated with INVEGA SUSTENNA."},{"name":"SPRAVATO (esketamine)","type":"service","description":"Nasal spray for treatment-resistant depression and MDD with suicidal ideation in adults."},{"name":"EDURANT (rilpivirine)","type":"service","description":"Antiretroviral medicine for HIV treatment in combination with other antiretrovirals."},{"name":"PREZISTA (darunavir)","type":"service","description":"Antiretroviral medicine for HIV treatment."},{"name":"PREZCOBIX / REZOLSTA (darunavir/cobicistat)","type":"service","description":"Antiretroviral combination medicine for HIV treatment."},{"name":"SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)","type":"service","description":"Once-daily single tablet regimen for HIV treatment."},{"name":"OPSUMIT (macitentan) / OPSYNVI (macitentan/tadalafil)","type":"service","description":"Long-term treatment for pulmonary arterial hypertension."},{"name":"UPTRAVI (selexipag)","type":"service","description":"Oral and intravenous selective IP receptor agonist for pulmonary arterial hypertension."},{"name":"XARELTO (rivaroxaban)","type":"service","description":"Oral anticoagulant for DVT, PE prevention, stroke reduction, and cardiovascular events."},{"name":"ACUVUE","type":"hardware","description":"Brand of contact lenses sold through eye care professionals globally."},{"name":"TECNIS","type":"hardware","description":"Premium intraocular lenses for cataract surgery."},{"name":"Abiomed","type":"hardware","description":"Mechanical circulatory support technologies for cardiogenic shock and high-risk PCI procedures."},{"name":"Shockwave","type":"hardware","description":"Circulatory restoration products for calcified coronary artery disease and peripheral artery disease."},{"name":"Mentor","type":"hardware","description":"Solutions for breast aesthetics and reconstruction within the Surgery portfolio."}],"partnerships":[{"partner_name":"Genmab A/S","partnership_type":"licensing","description":"Exclusive license to two DARZALEX patent families; royalty rate 12%-20% of net sales, ~$2.4B paid in fiscal 2025.","start_date":null}],"affiliations":[],"origin":{"leaf":"2f542d4f09d206242672d09a0ffd26605a3b17f1528bcf4877a6e1f13eded0f9","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"29e5509379931b80bbc4d1d08b16ef4cc48107b0a1d41940acbbe6b2a4d3876b","parent":"79d18ad1623f98b8ea01e98bcc38db059f8f482679a69df29dd7d23b477d4527","source":"0000200406-26-000016","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":88,"hourly_limit":500,"remaining":412,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}